Point72 Asset Management Takes 5.0% Stake in Sagimet Biosciences

TL;DR

**Point72 just bought 5% of Sagimet Biosciences, signaling a big institutional bet.**

AI Summary

Point72 Asset Management, L.P., a hedge fund based in Stamford, CT, has disclosed a significant stake in Sagimet Biosciences Inc. (NASDAQ: SGMT). As of February 2, 2024, Point72 beneficially owns 1,612,639 shares of Sagimet's Series A Common Stock, representing 5.0% of the company's outstanding shares. This filing indicates a notable institutional investor sees potential value in Sagimet, which could signal confidence in the biotech company's future prospects and potentially attract other investors.

Why It Matters

This matters because a major institutional investor like Point72 Asset Management taking a 5.0% stake can be seen as a vote of confidence, potentially driving up investor interest and the stock price for Sagimet Biosciences.

Risk Assessment

Risk Level: low — This filing generally indicates a positive development as a large institutional investor has taken a significant stake, which is typically not a high-risk event for existing shareholders.

Analyst Insight

A smart investor would view this as a positive signal, potentially researching Sagimet Biosciences Inc. further to understand the reasons behind Point72's investment and consider if it aligns with their own investment thesis.

Key Numbers

• 1,612,639 — Shares Beneficially Owned (The total number of Sagimet Biosciences shares Point72 Asset Management now controls.)
• 5.0% — Percentage of Class Outstanding (The proportion of Sagimet Biosciences' Series A Common Stock owned by Point72 Asset Management.)
• February 2, 2024 — Date of Event (The specific date that triggered the requirement for Point72 Asset Management to file this SC 13G.)

Key Players & Entities

• Point72 Asset Management, L.P. (company) — the reporting person acquiring shares
• Sagimet Biosciences Inc. (company) — the subject company whose shares were acquired
• 1,612,639 (dollar_amount) — number of shares beneficially owned
• 5.0% (dollar_amount) — percentage of class outstanding
• February 2, 2024 (person) — date of event requiring the filing
• Delaware (company) — place of organization for Point72 Asset Management

Forward-Looking Statements

• Increased institutional interest in Sagimet Biosciences Inc. (SGMT) will follow this disclosure. (Sagimet Biosciences Inc.) — medium confidence, target: Q2 2024
• The stock price of Sagimet Biosciences Inc. (SGMT) will experience a short-term positive reaction. (Sagimet Biosciences Inc.) — medium confidence, target: February 2024

FAQ

Key Financial Figures

• $0.0001 — uer) Series A Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• p24-0676sc13g.htm (SC 13G) — 60KB
• exhibit_99.htm (EX-99) — 6KB
• 0000902664-24-001054.txt ( ) — 67KB

(a)

Item 1(a). Name of Issuer. Sagimet Biosciences Inc. (the " Issuer ").

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. 155 Bovet Road, Suite 303, San Mateo, CA 94402.

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Point72 Asset Management, L.P. (" Point72 Asset Management ") with respect to shares of Series A common stock, par value $0.0001 per share (" Series A Common Stock "), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (" Point72 Associates "); (ii) Point72 Capital Advisors, Inc. (" Point72 Capital Advisors Inc .") with respect to Series A Common Stock held by Point72 Associates; and (iii) Steven A. Cohen (" Mr. Cohen ") with respect to Series A Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1 , pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

(c)

Item 2(c). Place of Organization. Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.

(d)

Item 2(d). Title of Class of Securities. Series A Common Stock, par value $0.0001 per share.

(e)

Item 2(e). CUSIP Number. 786700104 Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: Not applicable. CUSIP No. 786700104 13G Page 6 of 7 Pages Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on February 2, 2024. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Series A Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this 13 of the Act, the beneficial owner of the Series A Common Stock reported herein. Item 5. If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Series A Common Stock. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable. Item 8. Identification and Classification of Members of the

View Full Filing

View this SC 13G filing on SEC EDGAR